Magnyl

Acetylsalicylic acid, the active ingredient in Magnyl, is a non‑steroidal anti‑inflammatory drug presented as an oral tablet for oral use. It provides analgesic, antipyretic, anti‑inflammatory and antiplatelet effects for adults requiring pain relief, fever reduction or cardiovascular protection. GNH USA supplies Magnyl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Magnyl, an NSAID that inhibits platelet aggregation and prostaglandin synthesis, is employed in several clinical contexts: - Pain relief: reduces mild to moderate pain such as headache or musculoskeletal discomfort. - Fever reduction: lowers elevated body temperature associated with infection or inflammation. - Inflammation reduction: alleviates inflammatory swelling in conditions like arthritis. - Prevention of arterial thrombosis: lowers risk of recurrent myocardial infarction or ischemic stroke in patients with established cardiovascular disease.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: dyspepsia, abdominal pain. - Nausea or vomiting. - Minor bruising or bleeding from gums. - Mild headache. - Rash or mild skin irritation.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Severe hypersensitivity reactions, including anaphylaxis. - Hemorrhagic stroke. - Renal impairment or failure. - Hepatotoxicity. - Reye's syndrome in children with viral illness.

Before using Magnyl, consider the following safety measures: - Assess bleeding risk: avoid in patients with active ulcers or coagulopathy. - Evaluate renal function: adjust use in chronic kidney disease. - Monitor hepatic status: caution in liver impairment. - Review concomitant NSAIDs or anticoagulants: increased bleeding potential. - Avoid use in children with viral infections: risk of Reye's syndrome. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Magnyl can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Corticosteroids: increased ulceration potential.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): modestly increased bleeding. - ACE inhibitors or diuretics: possible reduction in renal perfusion. - Methotrexate: decreased clearance leading to toxicity.